期刊文献+

粒细胞集落刺激因子致血小板计数异常的文献病例分析 被引量:1

Literature Case Analysis of Platelet Count Abnormality Induced by Granulocyte Colony Stimulating Factor
原文传递
导出
摘要 目的分析粒细胞集落刺激因子致血小板计数异常(减少或增多)的发生特点,为其临床安全使用提供参考。方法检索建库至2021年1月7日MEDLINE、中国知网、万方、维普和中国生物医学文献数据库发表的关于粒细胞集落刺激因子致血小板计数异常的病例报道并进行统计和描述性分析。结果粒细胞集落刺激因子致血小板计数异常的病例报道共计11例,均发生在使用粒细胞集落刺激因子期间,其中男性8例(72.7%),女性3例(27.3%);年龄4 d~75岁(39.5±24.9)岁;引起血小板计数减少的有7例(63.6%),引起血小板计数增多的有4例(36.4%);出现并发症的有8例(72.7%),以血栓和出血事件居多;所有病例经停药、减量和对症治疗后血小板计数均有明显改善且并发症消退。结论粒细胞集落刺激因子致血小板计数异常较为罕见,其中以血小板减少相对多见。临床在使用粒细胞集落刺激因子期间应加强对血小板计数的监测,一旦发现异常变化应及时停药和对症处理,减少血栓或出血事件的发生。 OBJECTIVE To analyze the characteristics of platelet count abnormality(decrease or increase) induced by granulocyte colony stimulating factor(G-CSF) in order to provide references for its clinical rational drug use. METHODS MEDLINE, CNKI, Wanfang, VIP and CMB from the establishment of each database to January 7, 2021 were searched for platelet count abnormality induced by G-CSF, and the collected literatures were further analyzed statistically. RESULTS A total of 11 cases were identified and included in the analysis, all of which occurred during the period of using G-CSF. Among them, there were 8 males(72.7%) and 3 females(27.3%);aged from 4 days to 75 years old;7 cases(63.6%) decreased and 4 cases(36.4%) increased;8 cases(72.7%) had complications, most of which were thrombosis and bleeding events. The platelet count were significantly improved and the complications were resolved after withdrawal, reduction and symptomatic treatment in all cases. CONCLUSION Platelet count abnormality caused by G-CSF is relatively rare, and decrease is more common among them. The monitoring of platelet count should be strengthened during using G-CSF. Once platelet count abnormality occurs, G-CSF should be stopped and and symptomatic treatment should be given to reduce the risk of thrombosis or bleeding events.
作者 谢诚 夏凡 缪丽燕 XIE Cheng;XIA Fan;MIAO Liyan(Department of Pharmacy,the First Affiliated Hospital of Soochow University,Suzhou 215006,China)
出处 《中国现代应用药学》 CAS CSCD 北大核心 2021年第14期1763-1766,共4页 Chinese Journal of Modern Applied Pharmacy
基金 国家临床重点专科(临床药学)建设项目(国卫办医函[2018]292号)。
关键词 粒细胞集落刺激因子 血小板计数 异常 药品不良反应 文献病例分析 granulocyte colony stimulating factor platelet count abnormality adverse drug reaction literature case analysis
  • 相关文献

参考文献4

二级参考文献69

  • 1石远凯,刘鹏,杨晟,韩晓红,何小慧,艾斌,秦燕,李博,黄鼎智,张长弓,孙燕.注射用聚乙二醇化重组人粒细胞集落刺激因子I期临床耐受性试验[J].癌症,2006,25(4):495-500. 被引量:31
  • 2阎嶂松,李大鹏,姜尔烈,周春林,冯四洲,陈辉树,李忠廉,韩明哲.经粒细胞集落刺激因子动员的正常供者自发性脾破裂一例——附文献复习[J].中华血液学杂志,2006,27(12):829-832. 被引量:8
  • 3石远凯,何小慧,杨晟,王华庆,江泽飞,朱允中,克晓燕,张阳,刘云鹏,张伟京,王昭,石庆芝,谢晓冬,张贺龙,王杰军,罗德云,郑青山,孙瑞元.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少症的多中心随机对照Ⅱ期临床研究[J].中华医学杂志,2006,86(48):3414-3419. 被引量:43
  • 4http://www.cibmtr.org.
  • 5Yan CH, Xu LP, Wang FR, et al. Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation [J]. Bone Marrow Transplant, 2016, 51 (3) :391- 397. doi: 10.1038/bmt.2015.306.
  • 6Bassan R, Spinelli O, Oldani E, et al. Improved risk classifica- tion for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) [J]. Blood, 2009, 113 (18):4153-4162. doi: 10.1182/blood-2008-11-185132.
  • 7Zhao XS, Yan CH, Liu DH, et al. Combined use of WT1 and flow eytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity [J]. Ann Hematol, 2013, 92 (8):1111-1119. doi: 10.1007/s00277- 013-1733-1.
  • 8Chen H, Liu KY, Xu LP, et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome- positive acute lymphobla stic leukemia [J]. J Hematol Oncol, 2012, 5:29. doi: 10.1186/1756-8722-5-29.
  • 9Huang X J, Xu LP, Liu KY, et al. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia [J]. Biol Blood Marrow Transplant, 2011, 17 (5):649-656. doi: 10.1016/j.bbmt.2010. 07.023.
  • 10Yin JA, O'Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial[J]. Blood, 2012, 120( 14): 2826-2835. doi: 10.1182/blood-2012-06-435669.

共引文献59

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部